UroGen Pharma URGN Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by UroGen Pharma in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: UroGen Pharma’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about UroGen Pharma's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is UroGen Pharma's additional paid-in capital?
- UroGen Pharma (URGN) reported additional paid-in capital of $858.9M in Q1 2026.
- How has UroGen Pharma's additional paid-in capital changed year-over-year?
- UroGen Pharma's additional paid-in capital increased by 6.9% year-over-year, from $803.47M to $858.9M.
- What is the long-term trend for UroGen Pharma's additional paid-in capital?
- Over 5 years (2020 to 2025), UroGen Pharma's additional paid-in capital has grown at a 13.5% compound annual growth rate (CAGR), from $452.53M to $854.09M.
- What does additional paid-in capital mean?
- This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.